Filing Details

Accession Number:
0001225208-18-012682
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-08-16 17:51:10
Reporting Period:
2018-08-14
Accepted Time:
2018-08-16 17:51:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1201715 Jr Leonard G Baker 755 Page Mill Road, Suite A-200
Palo Alto CA 94304-1005
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-14 100,000 $12.47 876,838 No 4 P Direct
Common Stock Acquisiton 2018-08-15 79,686 $12.49 2,693,320 No 4 P Indirect By Ltd Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect By Ltd Partnership
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 955,055 Indirect By Trust
Footnotes
  1. The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the sales of shares by the reporting person, to the extent of the reporting person's pecuniary interest therein, at prices ranging from $16.00 to $16.22, inclusive, on May 11, 2018. The reporting person has paid to the Issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.40 to $12.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reporting person has paid to the issuer the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
  4. Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein.
  5. Shares held by a trust of which the reporting person is a trustee. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the trust.